Epigenomic causal inference is the application of statistical methods, most notably Mendelian randomization (MR), to determine whether an observed association between an epigenomic mark—such as DNA methylation or histone modification—and a complex trait reflects a genuine causal mechanism. It uses genetic variants as instrumental variables to proxy for the epigenomic exposure, thereby circumventing confounding from environmental factors and reverse causation that plague observational epigenome-wide association studies.
Glossary
Epigenomic Causal Inference
The application of statistical frameworks, notably Mendelian randomization, to disentangle causal relationships between epigenomic modifications and phenotypic outcomes from non-causal associations driven by confounding or reverse causation.
CAUSAL DISCOVERY IN REGULATORY GENOMICS
What is Epigenomic Causal Inference?
A statistical framework for distinguishing causal relationships between epigenomic marks and phenotypic traits from non-causal correlations, often leveraging genetic variants as instrumental variables.
This framework integrates quantitative trait loci (QTLs) for epigenomic features with genome-wide association study (GWAS) summary statistics for diseases. By testing whether a genetic variant that reliably alters a specific chromatin state also proportionally influences disease risk, researchers can prioritize causal regulatory elements for therapeutic targeting. Advanced methods extend this logic to cis- and trans-acting regulatory networks, using colocalization analyses and multivariable MR to dissect the independent causal effects of correlated epigenomic marks within a genomic locus.
CAUSAL DISCOVERY
Core Methodologies in Epigenomic Causal Inference
Statistical frameworks that distinguish causal relationships between epigenomic marks and phenotypic traits from mere correlations, moving beyond prediction to mechanistic understanding.
01
Mendelian Randomization (MR)
An instrumental variable method that uses germline genetic variants as proxies for modifiable epigenomic exposures. By leveraging the random assortment of alleles at conception, MR mimics a natural randomized controlled trial. A genetic variant robustly associated with DNA methylation at a specific CpG site serves as an instrument to test whether that methylation causally influences a downstream trait like disease risk. The core assumptions require the variant to be associated with the exposure, have no confounders, and affect the outcome only through the exposure.
3 Core Assumptions
Relevance, Independence, Exclusion Restriction
02
Two-Sample MR
A widely adopted MR design where summary-level GWAS data from two independent cohorts are harmonized. The genetic variant-exposure associations are extracted from an epigenomic GWAS (eGWAS), while variant-outcome associations come from a separate disease GWAS. This approach dramatically increases statistical power by leveraging massive publicly available consortia data without requiring individual-level measurements of both epigenomic marks and outcomes in the same participants.
2 Independent Cohorts
Exposure & Outcome Sources
03
Bidirectional MR
A framework that tests the directionality of a causal effect by running MR analyses in both directions. First, an epigenomic mark is tested as the exposure and a trait as the outcome. Then, the trait is tested as the exposure and the epigenomic mark as the outcome. This helps disentangle whether DNA methylation changes drive disease or whether disease onset causes secondary epigenetic alterations, a critical distinction for identifying therapeutic targets versus biomarkers.
04
Multivariable MR (MVMR)
An extension of MR that estimates the direct causal effect of each exposure in a set of correlated risk factors. In epigenomics, MVMR can simultaneously model multiple CpG sites within a genomic region to determine which specific methylation site independently influences the outcome. This addresses the challenge of high linkage disequilibrium and correlation among nearby methylation quantitative trait loci (mQTLs).
05
Colocalization Analysis
A Bayesian statistical method that assesses whether two association signals—such as an eQTL for an epigenomic mark and a GWAS locus for a disease—share the same causal variant. Colocalization provides evidence that a genetic variant influences both the epigenomic intermediate and the phenotype through a shared biological mechanism, strengthening causal inference beyond MR alone. Posterior probabilities quantify support for distinct hypotheses.
5 Hypotheses
H0–H4 Colocalization Models
06
Mediation Analysis
A regression-based framework that decomposes the total effect of an exposure on an outcome into direct and indirect effects. In epigenomic causal inference, mediation analysis quantifies the proportion of a genetic variant's effect on a phenotype that operates through an epigenomic intermediate. This requires careful adjustment for exposure-outcome confounding and mediator-outcome confounding, often addressed through sequential ignorability assumptions or causal mediation sensitivity analyses.
CAUSAL INFERENCE IN EPIGENOMICS
Frequently Asked Questions
Clear, technically precise answers to the most common questions about distinguishing causal epigenomic mechanisms from statistical correlations using methods like Mendelian randomization and instrumental variable analysis.
Epigenomic causal inference is the application of statistical frameworks, primarily Mendelian randomization (MR), to determine whether an epigenomic mark (e.g., DNA methylation at a specific CpG site) exerts a direct causal effect on a phenotypic trait or disease outcome, rather than merely being correlated with it. Standard epigenome-wide association studies (EWAS) identify associations between epigenetic variation and traits, but these are highly susceptible to confounding (where a third factor like age or smoking drives both) and reverse causation (where the disease alters the epigenome). Causal inference methods treat genetic variants—typically methylation quantitative trait loci (mQTLs)—as instrumental variables that proxy for the epigenomic exposure. Because germline genetic variants are fixed at conception and randomly assorted at meiosis, they are not influenced by postnatal confounders or disease processes. This allows researchers to triangulate evidence and prioritize epigenomic targets for therapeutic intervention with greater confidence than association alone permits.
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.
Enterprise searchRAGPermissions
Read more
Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.
AI agentsWorkflow automationGovernance
Read more
Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
AI integrationDecision supportModel routing
Read more
About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
LinkedIn
Limited slotsGet a Free AI Consultation
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us